Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.46 |
| ▸ | RHOC | P08134 | 4/20 | 0.44 |
| ▸ | RHOA | P61586 | 4/20 | 0.44 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.41 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.41 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.41 |
| ▸ | METAP2 | P50579 | 1/20 | 0.40 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.39 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1578844 | 1.00 | GPR52 (0.55) | GPR52EPHX2RHOCRHOATLR8 | |
| SCHEMBL1578491 | 0.82 | LMNA (0.40) | GPR52RHOCRHOAMRGPRX4 | |
| SCHEMBL1578975 | 0.81 | MRGPRX4 (0.57) | GPR52EPHX2RHOCRHOAMRGPRX4 | |
| SCHEMBL30794508 | 0.81 | MRGPRX4 (0.57) | GPR52EPHX2RHOCRHOAMRGPRX4 | |
| SCHEMBL2511779 | 0.77 | GLA (0.43) | EPHX2RHOCRHOAMRGPRX4 | |
| SCHEMBL18950260 | 0.75 | RHOC (0.41) | RHOCRHOADDR1 | |
| SCHEMBL1578715 | 0.73 | ICMT (0.39) | RHOCRHOATLR8ALDH1A1 | |
| SCHEMBL449608 | 0.72 | GSTO1 (0.58) | ALDH1A1MAPT | |
| SCHEMBL24349500 | 0.71 | GPR52 (1.00) | GPR52 | |
| SCHEMBL1578526 | 0.71 | ERCC1 (0.42) | ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4584250-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | Biohaven Therapeutics Ltd. (VG) | 2025-07-16 | — | — | EP | disclosed |
| EP-4580679-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | Biohaven Therapeutics Ltd. (VG) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |